With an FDA advisory committee recommendation in hand, Lundbeck and Otsuka’s Rexulti is one step closer to locking down a new indication in Alzheimer’s disease related agitation. In a 9-1 vote on ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the Joint Meeting of the ...

For the first time, the Food and Drug Administration has approved a drug to treat agitation related to Alzheimer’s disease dementia. Patient advocates are hailing the news, but prescribing the drug, ...

Rexulti (brexpiprazole) is a medication used to treat conditions like major depressive disorder (MDD), schizophrenia, and agitation associated with Alzheimer’s disease. Many Medicare Part D and ...

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted a supplemental new drug application from Otsuka and Lundbeck for Rexulti in combination ...

WASHINGTON (TND) — A medication has been approved to treat symptoms of dementia, theU.S. Food and Drug Administration (FDA) announced Thursday. The agency said Rexulti, an oral tablet, marks thefirst ...

Agitation is one of the most common symptoms of Alzheimer’s disease, leading patients to become restless or even verbally and physically aggressive. The FDA has approved the first drug to treat these ...

The list price of Rexulti is $1,419 per month. However, people can pay much less through a prescription drug plan (PDP), also known as Medicare Part D. According to the manufacturers of the drug, the ...

In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast ...